Just sent the following out with stocktwits.com to twitter.com...

$LDSR Short Term 40% Buy; Medium Term 25% Buy; Long Term 100% Buy http://quote.barchart.com/texpert.asp?sym=LDSR&code=BSTK

$HTDS Short Term 20% Buy; Medium Term 25% Buy; Long Term 100% Buy; Overall 48% Buy http://quote.barchart.com/texpert.asp?sym=HTDS&code=BSTK

$CTIC Short Term HOLD; Medium Term 75% Buy; Long Term 67% Buy; Overall 48% Buy http://quote.barchart.com/texpert.asp?sym=CTIC&code=BST... Read More

0 comments View Entry

The FDA has fallen weeks behind schedule in responding to select NDA's and PDUFA's. While people across the globe continue to fall ill, suffer and die from disease and debilitations, American drug research and development companies such as Cell Therapeutics (NASDAQ:CTIC), Hemispherx Biopharma (AMEX:HEB), BioDelivery Sciences International (NASDAQ:BDSI), Discovery Laboratories (NASDAQ:DSCO), Acura Phamaceuticals (NASDAQ:ACUR), King Pharmaceuticals (NYSE:KG) and Genta (OTC:GNTA) sit by anxiousl... Read More

0 comments View Entry

Following the close of market, biotech stock investors were excited and filled with a new breath of reassurance for their investment holdings in Cell Therapuetics (NASDAQ:CTIC) and Hemispherx Biopharma (AMEX:HEB) today. Given a sharp boost by their inclusion today in the Russell 3000, Cell Therapeutics closed at $1.85 (+0.28 +17.83%) while Hemispherx took the stage at $2.85 (+0.45 +18.75%).

The real buzz and excitement followed after hours for Hemispherx investors. Reports of after hou... Read More

0 comments View Entry